October 2023 updates to the website

The website has now been updated following October's LSCMMG

The following guidelines have been added/updated:

Free of charge (FOC) medicines schemes – national policy recommendations for local systems - Updated

Restless legs guidance - Update to follow in November

Melatonin prescribing information sheet and Melatonin position statement - removed and replaced with Melatonin pathway (children)

The following medicines have been updated following the Commissioning Resource Group (CRG) meeting:

Brimonidine gel - Symptomatic treatment of moderate to severe facial erythema of rosacea in adult patients

Ibandronic acid Tablets - adjuvant treatment of early breast cancer in postmenopausal women with a high risk of recurrence (unlicensed indication)

Flupentixol dihydrochloride - Treatment of schizophrenia and psychoses

Fluoride (sodium) 1.1%toothpaste - Treatment of head and neck cancer patients who have had surgery, radiotherapy and/or chemotherapy

Bempedoic acid with ezetimibe - for treating primary hypercholesterolaemia or mixed dyslipidaemia (NICE TA694)

Cenobamate - Treating focal onset seizures in epilepsy (NICE TA753)

Melatonin - Multiple indications in children (see entry for all indications listed)

The following Items will be updated and added to the website following the next Commissioning Resource Group (CRG) Meeting:

Bempedoic acid (without ezetimibe) - Treatment of primary hypercholesterolaemia or mixed dyslipidaemia